Sponsor:
University of Illinois at Chicago
Code:
NCT03121001
Conditions
Sickle Cell Disease
Eligibility Criteria
Sex: All
Age: 16 - 60
Healthy Volunteers: Not accepted
Interventions
ATG
fludarabine
cyclophosphamide
Total body irradiation
Stem cell infusion
Brief summary:
Conditions
Sickle Cell Disease
Study ID
NCT03121001
Start date
Mar 20, 2017
Status verified date
Jul, 2026
Completion date
May, 2029
Anticipated
Primary completion date
May, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 16 - 60
Healthy Volunteers: Not accepted
Enrollment
50 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: Subject treatment
Interventions
ATG
fludarabine
cyclophosphamide
Total body irradiation
Stem cell infusion
Sirolimus
mycophenolate mofetil
Primary outcome measure
Central contacts
Locations
University of Illinois at Chicago
Recruiting
Chicago, Illinois, United States, 60612
Contacts
Sponsor
University of Illinois at Chicago
Last update posted
Jul 8, 2026
Last verified
Jul, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by University of Illinois at Chicago on 2026-07-08.